In a 2‐day focus workshop of the German Society for Allergology and Clinical Immunology (DGAKI), the state of the art was discussed and practical recommendations for diagnosis and treatment of eosinophilic diseases, with a particular focus on new biologics, such as anti‐interleukin 5 and anti‐interleukin 5R, were derived. The gene discussed is IL5; the disease is eosinophil disorder.